E Fund Management (HK)’s Ascendis Pharma A/S ASND Stock Holding History

E Fund Management (HK)’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.4K	Buy	84 +24	+40%	+$5.61K	0.01%	293
2026 Q1	$13.7K	Buy	+60	New	+$13.4K	0.01%	287

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

E Fund Management (HK)'s ASND Position: Q2 2026 in Review

E Fund Management (HK) increased its Ascendis Pharma A/S (ASND) stake by 40% in Q2 2026, buying an estimated $5.61K and bringing the position to 84 shares worth $22.4K. The position accounts for 0.01% of the portfolio, ranked #293.

E Fund Management (HK) first reported a position in ASND in Q1 2026 and has held it in 2 quarters since. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

E Fund Management (HK) held 84 shares of Ascendis Pharma A/S worth $22.4K as of Q2 2026.
E Fund Management (HK) bought 24 Ascendis Pharma A/S shares in Q2 2026, an estimated $5.61K.
Ascendis Pharma A/S made up 0.01% of E Fund Management (HK)'s portfolio in Q2 2026, its #293 holding.
E Fund Management (HK) first reported a position in Ascendis Pharma A/S in Q1 2026 and has held it in 2 quarters since.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on E Fund Management (HK)'s 13F filing for Q2 2026, filed 22 Jul 2026.